WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.)

Shanghai, China
Small Molecule API Advanced Pharmaceutical Intermediates HPAPI ADC Payload / Linker (e.g., MMAE, Exatecan, Mafodotin) Oligonucleotide Drug Product (via PDS merger) Formulation Development Clinical Trial Material
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.)

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Shanghai, China
Modalities
Small Molecule API, Advanced Pharmaceutical Intermediates, HPAPI, ADC Payload / Linker (e.g., MMAE, Exatecan, Mafodotin), Oligonucleotide, Drug Product (via PDS merger), Formulation Development, Clinical Trial Material
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.)

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, Advanced Pharmaceutical Intermediates, HPAPI, ADC Payload / Linker (e.g., MMAE, Exatecan, Mafodotin), Oligonucleotide, Drug Product (via PDS merger), Formulation Development, Clinical Trial Material
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (8 modalities)

Frequently Asked Questions About WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.)

What is WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.)'s CDMO Signal Score?
WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.) for a manufacturing program?
Use the free AI matchmaker to compare WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
HPAPI CDMOs → ADC Payload / Linker (e.g., MMAE, Exatecan, Mafodotin) CDMOs → Oligonucleotide CDMOs →

Similar CDMOs

Veranova
Devens, MA
Small Molecule API, HPAPI, ADC payload/linker, Oligonucleotide, Peptide
EUROAPI
Paris, France
Small Molecule API, Microbial Fermentation API, Oligonucleotide, Peptide, HPAPI
Asymchem / AsymBio
Morrisville, NC (US HQ); Tianjin, China (primary manufacturing)
Glycan GMP synthesis, Glyco-remodeling ADC conjugation (GlycoConnect, GlycoT, DisacLink, iGDC platforms), Oligonucleotide, Small Molecule API, Peptide, ADC / Bioconjugates, Flow chemistry
Fermion (Orion Group)
Espoo, Finland
Small Molecule API, HPAPI, Semi-solid drug product (creams, gels, ointments), Hormonal products
Sai Life Sciences
Hyderabad, India
Small Molecule API, Complex Small Molecules, HPAPI, ADC, Peptides, Oligonucleotides, Lipids / LNP, Intermediates, Drug Discovery (CRO)